The AMACR Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A-549 lung adenocarcinoma cells with targeted disruption of the AMACR gene. This heterogeneous knockout model, lacking clonal selection, provides a loss-of-function system for studying alpha-methylacyl-CoA racemase biology in a genetically diverse cell pool. The polyclonal nature avoids clone-specific artifacts, making it suitable for functional genomics and drug screening applications.
The parental A-549 cell line, derived from a 58-year-old Caucasian male with lung carcinoma, displays adherent epithelial morphology and serves as a standard model for human lung adenocarcinoma. Extensively characterized in cancer research and drug testing, A-549 cells retain key epithelial features and metabolic pathways, enabling comparative analyses between wild-type and AMACR-disrupted counterparts.
AMACR encodes a peroxisomal enzyme that racemizes (R)-methylacyl-CoA esters to the (S)-form, a prerequisite for peroxisomal beta-oxidation of branched-chain fatty acids including phytanic acid. The enzyme operates downstream of regulators such as PPAR??, SREBP-1c, androgen receptor, and NF-??B, and interacts with ACOX2, HSD17B4, and SCP2. Its activity generates pristanoyl-CoA and bile acid intermediates, linking fatty acid metabolism to energy homeostasis. Disruption in this knockout model halts the production of essential (S)-enantiomers, perturbing lipid catabolism.
In the A-549 lung adenocarcinoma context, AMACR knockout allows exploration of peroxisomal metabolism in tumorigenesis. Frequently overexpressed in prostate and colorectal cancers, AMACR’s role in lung cancer remains elusive; this model facilitates investigation of metabolic reprogramming, proliferation, and migration. The impaired degradation of phytanic acid and related lipids may reveal vulnerabilities in cancer cells reliant on branched-chain fatty acid oxidation for energy or redox balance.
Researchers can employ these polyclonal knockout cells for functional assays, including western blotting, RT-qPCR, and immunofluorescence to validate AMACR disruption, as well as phytanic acid oxidation assays to measure metabolic flux. Additional applications include proliferation, migration, and drug sensitivity testing to assess the impact of AMACR loss on cancer phenotypes and to screen for potential inhibitors. These cells provide a versatile platform for studying branched-chain fatty acid metabolism in lung adenocarcinoma. For technical inquiries, contact Ascent Research.
